Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Summary

RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent prostate cancer.

Timeline

Start

2004-06

Primary completion

2010-02

Completion

2010-03

Outcome

Outcome not reported

Stopped: “Closed for futility”

Drugs

Indications